written on 11.04.2014

Natco looking to block Indian patent for Gilead's Sovaldi


India may now be taking compulsory licensing one step further, with domestic Natco Pharma asking the country's patent office to deny Gilead Sciences protection on its brand-new hep C treatment in the first place.

Latest Reports